On Oct. 1, 2021, LabCorp announced that it had received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for a combined home collection kit that detects COVID-19 and influenza A/B simultaneously in individuals as young as 2 years of age.

The kit was to be available at no upfront cost to those who meet clinical guidelines, which may include experiencing symptoms, being exposed to someone with COVID-19 or if asked to be tested by a health care provider.